Mostrar el registro sencillo del ítem

dc.contributor.authorLópez Domínguez, Raúl 
dc.contributor.authorCarmona Sáez, Pedro 
dc.date.accessioned2021-05-26T07:40:35Z
dc.date.available2021-05-26T07:40:35Z
dc.date.issued2021
dc.identifier.citationLopez-Dominguez, R.; Toro-Dominguez, D.; Martorell-Marugan, J.; Garcia-Moreno, A.; Holland, C.H.; Saez-Rodriguez, J.; Goldman, D.; Petri, M.A.; Alarcon-Riquelme, M.E.; Carmona-Saez, P. Transcription Factor Activity Inference in Systemic Lupus Erythematosus. Life 2021, 11, 299. https://doi.org/10.3390/ life11040299es_ES
dc.identifier.urihttp://hdl.handle.net/10481/68730
dc.description.abstractBackground: Systemic Lupus Erythematosus (SLE) is a systemic autoimmune disease with diverse clinical manifestations. Although most of the SLE-associated loci are located in regulatory regions, there is a lack of global information about transcription factor (TFs) activities, the mode of regulation of the TFs, or the cell or sample-specific regulatory circuits. The aim of this work is to decipher TFs implicated in SLE. Methods: In order to decipher regulatory mechanisms in SLE, we have inferred TF activities from transcriptomic data for almost all human TFs, defined clusters of SLE patients based on the estimated TF activities and analyzed the differential activity patterns among SLE and healthy samples in two different cohorts. The Transcription Factor activity matrix was used to stratify SLE patients and define sets of TFs with statistically significant differential activity among the disease and control samples. Results: TF activities were able to identify two main subgroups of patients characterized by distinct neutrophil-to-lymphocyte ratio (NLR), with consistent patterns in two independent datasets—one from pediatric patients and other from adults. Furthermore, after contrasting all subgroups of patients and controls, we obtained a significant and robust list of 14 TFs implicated in the dysregulation of SLE by different mechanisms and pathways. Among them, well-known regulators of SLE, such as STAT or IRF, were found, but others suggest new pathways that might have important roles in SLE. Conclusions: These results provide a foundation to comprehend the regulatory mechanism underlying SLE and the established regulatory factors behind SLE heterogeneity that could be potential therapeutic targets.es_ES
dc.description.sponsorshipInnovative Medicines Initiative 2 Joint Undertaking (JU) - 831434 (3TR)es_ES
dc.description.sponsorshipEuropean Union’s Horizon 2020 research and innovation program and EFPIAes_ES
dc.description.sponsorshipNIH AR69572 and NIH RO-1 grant AR069572es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsAtribución 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectTranscription factor activity inferencees_ES
dc.subjectCluster analysis es_ES
dc.subjectSystemic lupus erythematosus es_ES
dc.subjectDisease classificationes_ES
dc.titleTranscription Factor Activity Inference in Systemic Lupus Erythematosuses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doi10.3390/life11040299


Ficheros en el ítem

[PDF]

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 3.0 España
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 3.0 España